Johns Hopkins Medicine: Immunotherapy Plus Chemotherapy Before Surgery Improves Outcomes for Patients With Lung Cancer
April 12, 2022
April 12, 2022
BALTIMORE, Maryland, April 12 (TNSJou) -- Johns Hopkins Medicine issued the following news release:
Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) -- the leading cause of cancer deaths worldwide -- reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial. It also achieved a nearly twelvefold increase in p . . .
Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) -- the leading cause of cancer deaths worldwide -- reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial. It also achieved a nearly twelvefold increase in p . . .